<DOC>
	<DOCNO>NCT00174967</DOCNO>
	<brief_summary>The purpose study determine efficacy febuxostat , daily ( QD ) , reduce serum urate level subject gout .</brief_summary>
	<brief_title>Dose-Response , Safety Efficacy Febuxostat Subjects With Gout</brief_title>
	<detailed_description>Gout chronic urate crystal deposition disorder , leave untreated may result progressive disease characterize joint bone destruction tophaceous deposit renal impairment due gouty nephropathy . Hyperuricemia , define serum urate concentration &gt; 7.0 milligram per deciliter ( mg/dL ) , underlie metabolic aberration lead urate crystal deposition gout . Gout several clinical presentation , include : recurrent acute attack inflammatory arthritis ; deposition monosodium urate monohydrate crystal joint , bone even parenchymal organ ( tophaceous gout ) ; renal impairment ; uric acid nephrolithiasis . As serum urate level increase beyond &gt; 7.0 mg/dL , risk gouty arthritis renal calculus increase . Currently allopurinol xanthine oxidase inhibitor available . Allopurinol agent choice reduction serum urate level patient : uric acid overproduction ; unresponsive intolerant uricosuric agent ; impair renal function ; uric acid urolithiasis ; tophus . Febuxostat ( TMX-67 ) non-purine selective xanthine oxidase inhibitor develop orally administer agent management hyperuricemia patient gout .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Hyperuricemia ( serum uric acid ≥8.0 mg/dL ) . Must meet American College Rheumatology criterion gout . Must adequate renal function ( serum creatinine &lt; 1.5 mg/dL ) . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . History xanthinuria Alcohol consumption &gt; 14/week Has history significant concomitant illness . Has active liver disease . Has body mass index great 50 kilogram per meter² ( kg/m² ) Any significant medical condition would interfere treatment , safety compliance protocol , define investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Uric Acid</keyword>
	<keyword>xanthine oxidase</keyword>
	<keyword>tophus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>